In rabbits, landiolol, a new ultra-short-acting β-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol

Abstract

Purpose: To compare the cardiovascular and sympathetic effects of a new ultra-short-acting, highly cardioselective β-blocker, landiolol, with esmolol, using an in vivo rabbit model. Methods: Different bolus doses of landiolol (0.3, 1.0, 3.0 and 10.0 mg·kg-1) or esmolol (0.5, 1.5 and 5.0 mg·kg-1) were given intravenously, and the effects on heart rate (HR) mean arterial pressure (MAP) and renal sympathetic nerve activity (RSNA) were compared. Results: Both landiolol and esmolol produced a dose-dependent decrease in HR. The maximum percent reductions of HR were similar with landiolol 3 mg·kg-1 and esmolol 5 mg·kg-1 (-14.0 ± 0.9% and -13.9 ± 1.4%, mean ± SE, respectively). HR decreased more rapidly with landiolol than with esmolol. Esmolol produced a dose-dependent decrease in MAP that was not observed with landiolol. The percent maximum reduction of MAP was -38.2 ± 3.2% with esmolol 5 mg·kg-1. RSNA increased in a dose-dependent fashion with esmolol, but no changes were noted with landiolol. Conclusion: These results suggest that, in rabbits, landiolol has slightly more potent negative chronotropic action than esmolol with significantly less effects on blood pressure.